<DOC>
	<DOCNO>NCT02475746</DOCNO>
	<brief_summary>The purpose study evaluate effect itraconazole multiple dose administration single dose PK PF-06372865 .</brief_summary>
	<brief_title>An Open-label , Two-period , Fixed-sequence Study Evaluate Multiple-dose Itraconazole Effect The Single-dose PK PF-06372865 Healthy Subjects</brief_title>
	<detailed_description>Study include two treatment period : period 1 single dose PF-06372865 give alone follow least 5-day washout . The period 2 200 mg QD itraconazole give 8 day PF-06372865 single dose co-administered day 4 ( 1 hour later itraconazole dose ) . The PK safety assess compare single dose PF-06372865 period 1 period 2 .</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Healthy female subject nonchildbearing potential and/or male subject , time Screening , age 18 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) Evidence personally sign date informed consent document indicate subject inform pertinent aspect study Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure Exclusion Criteria Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) Hypersensitivity previous adverse event due azole antifungal . A positive urine drug screen . History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week male ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month Screening . Use tobacco nicotine containing product past 6 month , evident positive urine Cotinine test Screening . Treatment investigational drug within 30 day ( determined local requirement 5 halflives precede first dose investigational product , whichever longer . Screening supine blood pressure 140 mm Hg ( systolic ) 90 mm Hg ( diastolic ) , follow least 5 minute supine rest . Screening supine 12lead ECG demonstrate QTc &gt; 450 msec QRS interval &gt; 120 msec Screening . Subjects ANY follow abnormality clinical laboratory test Screening AND Day 0 , assess studyspecific laboratory confirm single repeat , deem necessary : Aspartate aminotransferase ( AST ) /serum glutamic oxaloacetic transaminase ( SGOT ) alanine aminotransferase ( ALT ) / serum glutamic pyruvic transaminase ( SGPT ) &gt; 1x upper limit normal ( ULN ) ; Total bilirubin &gt; 1x ULN ; subject history Gilbert 's syndrome may direct bilirubin measure would eligible study provide direct bilirubin ULN . Pregnant female subject ; female childbearing potential ; breastfeed female subject ; male subject partner currently pregnant ; male subject able father child unwilling unable use highly effective method contraception outline protocol duration study least two month last dose Itraconazole Use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose investigational product . As exception , acetaminophen/paracetamol may use dos 1 g/day . Limited use nonprescription medication believe affect subject safety overall result study may permit casebycase basis follow approval sponsor . Herbal supplement hormone replacement therapy must discontinue least 28 day prior first dose investigational product Blood donation ( exclude plasma donation ) approximately 1 pint ( 500 mL ) within 56 day prior dose Unwilling unable comply Lifestyle Guidelines describe protocol Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study Subjects investigational site staff member directly involved conduct study family member , site staff member otherwise supervised investigator , subject Pfizer employee directly involve conduct study Any condition possibly affect drug absorption ( eg , gastrectomy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>drug interaction , PF-06372865 , itraconazole</keyword>
</DOC>